Edward Tenthoff
Stock Analyst at Piper Sandler
(2.21)
# 2,479
Out of 4,814 analysts
178
Total ratings
36.47%
Success rate
-4.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.54 | +270.37% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $9.34 | +414.19% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $10.23 | +134.60% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $32.20 | +142.24% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $10.58 | +183.55% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $12.08 | +272.52% | 11 | Nov 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $232.96 | +27.06% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $25.13 | +174.57% | 12 | Nov 18, 2024 | |
| KRON Kronos Bio | Downgrades: Neutral | $6 → $1 | $0.92 | +8.12% | 7 | Nov 14, 2024 | |
| TPST Tempest Therapeutics | Maintains: Overweight | $104 → $65 | $7.08 | +818.08% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.90 | +847.37% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.93 | +193.38% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $0.55 | +1,891.67% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.57 | +1,173.89% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.38 | +118.18% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.77 | +288.95% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.47 | +257.94% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $37.77 | +178.00% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.26 | +378.09% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.01 | +395.05% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $3.53 | +324.93% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $27.13 | +106.45% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $8.75 | +528.57% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $0.78 | +3,873.34% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.19 | +1,507.72% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.38 | +1,466.58% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.37 | +2,303.20% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.74 | +162.84% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.59 | +387.48% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112,332 → $32,560 | $0.64 | +5,121,812.85% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $595.28 | -40.53% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.06 | +12,634.65% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $477.52 | -32.36% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $35.59 | +1.15% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.20 | +1,983.33% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.60 | +25,110.08% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.28 | +4,040.63% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.63 | +218,947.62% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $561.49 | - | 11 | Feb 13, 2017 |
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.54
Upside: +270.37%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $9.34
Upside: +414.19%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $10.23
Upside: +134.60%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $32.20
Upside: +142.24%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $10.58
Upside: +183.55%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $12.08
Upside: +272.52%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $232.96
Upside: +27.06%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $25.13
Upside: +174.57%
Kronos Bio
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.92
Upside: +8.12%
Tempest Therapeutics
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $7.08
Upside: +818.08%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.90
Upside: +847.37%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $11.93
Upside: +193.38%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.55
Upside: +1,891.67%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.57
Upside: +1,173.89%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.38
Upside: +118.18%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.77
Upside: +288.95%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.47
Upside: +257.94%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $37.77
Upside: +178.00%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.26
Upside: +378.09%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.01
Upside: +395.05%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $3.53
Upside: +324.93%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $27.13
Upside: +106.45%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $8.75
Upside: +528.57%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $0.78
Upside: +3,873.34%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.19
Upside: +1,507.72%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.38
Upside: +1,466.58%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.37
Upside: +2,303.20%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.74
Upside: +162.84%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.59
Upside: +387.48%
May 13, 2022
Maintains: Overweight
Price Target: $112,332 → $32,560
Current: $0.64
Upside: +5,121,812.85%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $595.28
Upside: -40.53%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.06
Upside: +12,634.65%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $477.52
Upside: -32.36%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $35.59
Upside: +1.15%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.20
Upside: +1,983.33%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.60
Upside: +25,110.08%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.28
Upside: +4,040.63%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.63
Upside: +218,947.62%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $561.49
Upside: -